Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $0.69 by 73.91 percent. This is a 16.67 percent decrease over earnings of $1.44 per share from the same period last year. The company reported quarterly sales of $990.000 million which beat the analyst consensus estimate of $926.908 million by 6.81 percent. This is a 19.94 percent increase over sales of $825.410 million the same period last year.